Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585-594.

Publication Type:

Journal Article

Authors:

Everhart, J.E.; Wright, E.C.; Goodman, Z.D.; Dienstag, J.L.; Hoefs, J.C.; Kleiner, D.E.; Ghany, M.G.; Mills, A.S.; Nash, S.R.; Govindarajan, S.; Rogers, T.E.; Greenson, J.K.; Brunt, E.M.; Bonkovsky, H.L.; Morishima, C.; Litman, H.J.; HALT-C trial group

Source:

Hepatology, Volume 51, Issue 2, p.585-594 (2010)

Keywords:

Biopsy, Carcinoma, complications, Death, Disease, etiology, Fibrosis, Follow-Up Studies, Health, hepatitis, Hepatitis C, Hepatitis C,Chronic, Human, Humans, Incidence, Laboratories, Liver, Liver Cirrhosis, Liver Transplantation, pathology, Patients, peginterferon, Prognosis, Prospective Studies, Ribavirin, Severity of Illness Index, Time Factors, transplantation, treatment

Notes:

PMC3814134

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/20101752

Export Citation:

RIS Format

Top